Literature DB >> 17854742

Vascular complications of scleroderma.

Serena Guiducci1, Roberto Giacomelli, Marco Matucci Cerinic.   

Abstract

Systemic sclerosis (SSc) is a multiorgan disease characterized by injury to vascular wall and extensive damage of the microvessels. The injury of the vascular wall is characterized by the formation of megacapillaries and avascular areas. The reduced capillary density leads to clinical manifestations such as digital ulcers. These lesions are extremely painful and lead to substantial functional disability. Management of digital ulcers includes non-pharmacologic and pharmacologic modalities. Despite the reduced blood flow and reduced partial oxygen pressure levels, there is paradoxically no evidence for a sufficient angiogenesis in the skin of patients with SSc. Angiogenesis is strongly disturbed in SSc, as demonstrated by Nailfold Video-Capillaroscopy changes, the damage of the vessels evolves progressively from early to late stages and is characterized by different morphological aspects. Almost all patients develop Raynaud's phenomenon which, together with structural vasculopathy, results in ulceration and critical digital ischemia. Many of the severe internal organ complications of SSc are vascular, including pulmonary arterial hypertension (PAH) and scleroderma renal crisis. Structural vascular damage occurs in many vascular beds and contribute to pulmonary, renal, cardiac and gastrointestinal complications. SSc has a high case-specific mortality due to organ-based complications including PAH, lung fibrosis, renal failure and involvement of the gastrointestinal tract.

Entities:  

Mesh:

Year:  2007        PMID: 17854742     DOI: 10.1016/j.autrev.2006.12.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  33 in total

1.  Biomechanical podiatric evaluation in an Italian cohort of patients with systemic sclerosis: A pilot study.

Authors:  Susanna Maddali Bongi; Giovanni Ravenni; Benedetta Ciampi; Angela Del Rosso; Khadija El Aoufy
Journal:  Eur J Rheumatol       Date:  2016-12-01

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

5.  Bosentan fosters microvascular de-remodelling in systemic sclerosis.

Authors:  S Guiducci; S Bellando Randone; C Bruni; G Carnesecchi; A Maresta; F Iannone; G Lapadula; M Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2012-09-29       Impact factor: 2.980

6.  Semaphorin 3A: an immunoregulator in systemic sclerosis.

Authors:  Doron Rimar; Yuval Nov; Itzhak Rosner; Gleb Slobodin; Michael Rozenbaum; Katy Halasz; Tharwat Haj; Nizar Jiries; Lisa Kaly; Nina Boulman; Zahava Vadasz
Journal:  Rheumatol Int       Date:  2015-04-21       Impact factor: 2.631

Review 7.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

8.  The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.

Authors:  Edoardo Rosato; Federica Borghese; Simonetta Pisarri; Felice Salsano
Journal:  Clin Rheumatol       Date:  2009-08-20       Impact factor: 2.980

Review 9.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

10.  Lack of evidence for bacterial infections in skin in patients with systemic sclerosis.

Authors:  Maureen D Mayes; Judith A Whittum-Hudson; Cynthia Oszust; Hervé C Gérard; Alan P Hudson
Journal:  Am J Med Sci       Date:  2009-04       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.